HUMAN AMYLOID IMAGING CONFERENCE
January 17-19, 2018
The 12th Human Amyloid Imaging will take place in Miami, Florida on January 17-19, 2018. My co-organizers for the meeting will be, once more, Bill Klunk (University of Pittsburgh), Chet Mathis (University of Pittsburgh) and Bill Jagust (University of California, Berkeley).
At HAI 2018 we will continue to emphasize ample lively discussion of core controversies such as: what does the presence of brain amyloid mean, how should it be measured, how does it change, and what does it portend? Our discussions primarily sprung from brief presentations by active investigators who will report unpublished, cutting-edge research in human imaging of amyloid-beta and/or other biomarkers that pertain to Alzheimer’s-related disease.
To assemble HAI we will accept and peer-review only the most recent, important work, abstract submissions. The 2017 meeting drew more than 365 attendees and showcased 116 posters from research groups spanning North America, Europe, East Asia, and Australia.
Research reports are complemented at HAI by Keynote presentations that are intended to cross disciplines and provide perspective from neuropathology, neurochemistry, psychology, neurology, molecular imaging, clinical trials and biomarker research.
In 2018, we are pleased to welcome two such presentations from Drs. William Seeley (University of California, San Francisco) and Peter Davies (Northwell Health). In addition to these, we will continue our lectures on basic methods in amyloid PET.
Until our 12th edition of HAI, we invite you to bookmark our website, follow us on social media and save the dates in your calendars!
Keith A. Johnson, MD
Massachusetts General Hospital/Harvard Medical School
The 2017 edition of the HAI conference featured 42 podium presentations selected from submitted abstracts.
2017 keynote lecturers: Thomas Beach, Marc Diamond, Howard Feldman, and Roger Gunn.
The 2017 meeting registered 170 abstract submissions and showcased 116 posters from research groups from all over the world.
Each session of podium presentations were followed by a 30 minute panel discussion and Q&A session moderated by two co-chairs.
Attendees have the opportunity to review the basic, fundamental principles of amyloid PET imaging, including radiochemistry of amyloid agents, radio-tracer synthesis, PET acquisition and data processing, including application of corrections for the partial volume effect and co-registration with structural data.
The concept of amyloid positive will be extensively discussed, and the attendees should be able to characterize the advantages and disadvantages of both dichotomized and continuous variable approaches to amyloid PET analyses with respect to specific purposes or intended uses of the outcome.
Attendees will have the opportunity to evaluate amyloid PET data in specific clinical and clinical research contexts, including review of typical findings in Alzheimer’s disease dementia, mild cognitive impairment due to Alzheimer’s disease, and in clinically normal individuals. These phenomena will also be related to familial forms of the disease and to non-AD processes such as fronto-temporal lobar degeneration and dementia with Lewy Bodies.
Particular attention will be given to the assessment of longitudinal amyloid PET data as it relates to methods of analysis and comparison to other domains of data, including structural and functional brain imaging data, and clinical and cognitive outcomes.
- Abstract and scholarship application submission platform will open: October 16, 2017
- Abstract and scholarship application submission platform will close: November 6, 2017
- Abstracts will be reviewed between November 7, 2017 and November 24, 2017.
- Podium/Poster Presenter notification of acceptance: on or around December 1, 2017
- Travel scholarship notification: on or around December 4, 2017
HOTEL ROOM BLOCK
- DISCOUNT ROOM BLOCK RATES will be available through December 11, 2017 or earlier (should block sell out).
COUNTDOWN TO 2018 CONFERENCE